User login
CHICAGO – Research continues into whether the anesthetic ketamine will deliver on what some see as its potential to be a notably effective treatment for refractory depression, but other medical treatments are also under review.
Dr. James Jefferson scanned the depression treatment horizon in a presentation at Psychiatry Update 2014, sponsored by Current Psychiatry and the American Academy of Clinical Psychiatrists. In a video interview, Dr. Jefferson of the University of Wisconsin, Madison, forecasts what he thinks will – or won’t – enter the armamentarium. Might that include Botox? And how promising is the nutritional supplement SAMe?
Dr. Jefferson shares his thoughts on these and other contenders, and he considers when atypical antipsychotics are appropriate for treating depression. He also delivers stern words to clinicians who do not read the package inserts in the medications they prescribe.
Current Psychiatry and this news organization are owned by the same parent company.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @whitneymcknight
CHICAGO – Research continues into whether the anesthetic ketamine will deliver on what some see as its potential to be a notably effective treatment for refractory depression, but other medical treatments are also under review.
Dr. James Jefferson scanned the depression treatment horizon in a presentation at Psychiatry Update 2014, sponsored by Current Psychiatry and the American Academy of Clinical Psychiatrists. In a video interview, Dr. Jefferson of the University of Wisconsin, Madison, forecasts what he thinks will – or won’t – enter the armamentarium. Might that include Botox? And how promising is the nutritional supplement SAMe?
Dr. Jefferson shares his thoughts on these and other contenders, and he considers when atypical antipsychotics are appropriate for treating depression. He also delivers stern words to clinicians who do not read the package inserts in the medications they prescribe.
Current Psychiatry and this news organization are owned by the same parent company.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @whitneymcknight
CHICAGO – Research continues into whether the anesthetic ketamine will deliver on what some see as its potential to be a notably effective treatment for refractory depression, but other medical treatments are also under review.
Dr. James Jefferson scanned the depression treatment horizon in a presentation at Psychiatry Update 2014, sponsored by Current Psychiatry and the American Academy of Clinical Psychiatrists. In a video interview, Dr. Jefferson of the University of Wisconsin, Madison, forecasts what he thinks will – or won’t – enter the armamentarium. Might that include Botox? And how promising is the nutritional supplement SAMe?
Dr. Jefferson shares his thoughts on these and other contenders, and he considers when atypical antipsychotics are appropriate for treating depression. He also delivers stern words to clinicians who do not read the package inserts in the medications they prescribe.
Current Psychiatry and this news organization are owned by the same parent company.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @whitneymcknight
EXPERT ANALYSIS FROM PSYCHIATRY UPDATE 2014
